Wir sind mit live! Mehr erfahren

APUS

Apimeds Pharmaceuticals US

APUS

Börsenwert 6,1 Mio. $

4,04 USD

-0,35

7,97 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

4,10

+0,06

1,49 %

1 Tag

-7,97 %

5 Tage

-25,6 %

1 Monat

152,5 %

3 Monate

-38,32 %

6 Monate

-86,53 %

Seit Jahresbeginn

-75,81 %

1 Jahr

-78,04 %

5 Jahre

-81,64 %

10 Jahre

-81,64 %

Profil: Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.

Mitarbeiter: 7

Gesundheitswesen Arzneimittelhersteller – allgemein

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 14,3 %

Neutral 85,7 %

Negativ 0 %

NILA Token to Begin Trading on Pionex, Opening Access to Eligible Users Worldwide

Trading opens Wednesday, Oct. 14, 2026, at 6 a.m. ET on Pionex, a global cryptocurrency exchange known for its built-in automated trading bots Trading opens Wednesday, Oct. 14, 2026, at 6 a.m. ET on Pionex, a global cryptocurrency exchange known for its built-in automated trading bots

NILA Token to Begin Trading on Pionex, Opening Access to Eligible Users Worldwide

MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media

MATAWAN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- MindWave Innovations Inc. ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS), has signed a 12-month software development and technology services agreement with New York-based Flash Sports & Media Holdings, Inc. (FLZH) to build and operate FlashChain, a blockchain for tracking digital broadcasting rights, video assets and match ticket inventory.

MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media

Apimeds Pharmaceuticals Stock Skyrockets Thursday: What's Happening?

Apimeds Pharmaceuticals US Inc. (NYSE:APUS) shares are surging Thursday morning after its wholly owned subsidiary, MindWave Innovations Inc., announced a 12-month technology services agreement with Singapore-based AQUAE Holdings Pte. Ltd. to build and operate AQUAEChain.

Apimeds Pharmaceuticals Stock Skyrockets Thursday: What's Happening?

MindWave Innovations Signs Agreement to Build and Operate AQUAEChain, a Platform for Insured ALCI Credits

MindWave will supply and operate the technology, while AQUAE leads the ALCI Credits methodology, brand and market development MindWave will supply and operate the technology, while AQUAE leads the ALCI Credits methodology, brand and market development

MindWave Innovations Signs Agreement to Build and Operate AQUAEChain, a Platform for Insured ALCI Credits

IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.

AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy.

IBN Initiates Coverage of Apimeds Pharmaceuticals US, Inc.

NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange

MATAWAN, New Jersey / GEORGE TOWN, Cayman Islands, Aug. 03, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“MindWave Innovations Inc.” or the “Company”), today announced that its NILA token is now available to eligible users in the United States on Webot, a licensed U.S. cryptocurrency exchange. Starting today, eligible U.S. users may access NILA on a licensed American platform for the first time.

NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange

MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October

MATAWAN, New Jersey, and GEORGE TOWN, Cayman Islands, July 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("MindWave Innovations Inc" or the "Company"), today announced MindChain, the world's first fully insured blockchain. MindChain is an insured, production-grade, EVM-compatible Layer 2 network that will go live in October 2026.

MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Recognition Reflects Dedication, Collaboration, and Purpose-Driven Culture thatEmpower University Employees to Make Last Impacts on Global Students CHARLES TOWN, W.Va., June 8, 2026 /PRNewswire/ -- American Public University System (APUS) has again been certified as a Great Place to Work® , a recognition earned entirely through positive employee feedback.

For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

MATAWAN, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the “Inscobee Parties”), resolving all outstanding disputes arising from the APUS' December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company's previously disclosed $100 million PIPE financing, and the advancement.

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, April 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apimeds Pharmaceuticals US, Inc. (“Apimeds” or “the Company”) (NYSE American: APUS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt